WuXi XDC Cayman, Inc.
7.85
EUR
-0.80
(-9.25%)
WuXi XDC Cayman, Inc.
GETTEX:L74
(Gettex)
Recent
price
7.85
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- WuXi XDC Cayman Inc. is a leading global contract research, development and manufacturing organization focused on antibody drug conjugates and other bioconjugates. The company provides end-to-end services including discovery, process development and GMP manufacturing of bioconjugate drug substances and drug products; monoclonal antibody intermediates; payload-linkers associated with bioconjugates; and antibody intermediates and other biologics intermediates, supported by proprietary technology platforms such as the upgraded WuXiDARx and novel WuXiTecan-1 and WuXiTecan-2 linker-payload technologies. Founded in 2013 and headquartered in Wuxi, China, it operates facilities in China, North America, Europe and internationally, including a new Singapore site that achieved mechanical completion in June 2025 with GMP manufacturing planned for 2026, serving 419 customers worldwide as a subsidiary of WuXi Biologics (Cayman) Inc. Recent developments include the GMP release of its DP3 drug product facility at the Wuxi site in July 2025 to scale manufacturing capacity; a strategic partnership with IntoCell announced in early 2024 for drug-linker technologies and integrated CRDMO services; a memorandum of understanding with Standard Chartered China in November 2025 for financial collaboration; signing 37 new integrated projects and adding three process performance qualification projects in the first half of 2025; and share placements in September 2025 raising HK$2.71 billion to support expansion.